Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?

Science

Living robots made in a lab have found a new way to self-replicate, researchers say

Living robots made in a lab have found a new way to self-replicate, researchers say

Xenobots, a type of programmable organism made from frog cells, can replicate by spontaneously sweeping up loose stem cells, researchers say. This could have implications for regenerative medicine.
by Scott Neuman

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!
FDA panel narrowly backs COVID-19 pill from Merck

FDA panel narrowly backs COVID-19 pill from Merck

A panel of U.S. health advisers on Tuesday narrowly backed the benefits of a closely watched COVID-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans could take at home to treat the virus.
by The Associated Press

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!
How vaccine makers plan to address the new omicron coronavirus variant

How vaccine makers plan to address the new omicron coronavirus variant

Vaccine makers are already pivoting their efforts to combat new coronavirus variants: testing higher doses of booster shots, designing new boosters that anticipate strain mutations, and developing omicron-specific boosters.
by Dustin Jones

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!